{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:09:42Z","timestamp":1779084582909,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coi.2025.102601","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T14:08:18Z","timestamp":1751897298000},"page":"102601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Moving beyond the Janus kinase signaling kinases in the pathogenesis and treatment of psoriasis and psoriatic arthritis"],"prefix":"10.1016","volume":"95","author":[{"given":"Smriti K","family":"Raychaudhuri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Disha","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L","family":"Leonardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-6528","authenticated-orcid":false,"given":"Siba P","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102601_bib1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s40744-023-00602-9","article-title":"Psoriasis and psoriatic arthritis have a major impact on quality of life and depressive symptoms: a cross-sectional study of 300 patients","volume":"10","author":"Frede","year":"2023","journal-title":"Rheuma Ther"},{"key":"10.1016\/j.coi.2025.102601_bib2","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.coi.2025.102601_bib3","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheuma"},{"key":"10.1016\/j.coi.2025.102601_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102601_sbref5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.25259\/IJDVL_1152_2022","article-title":"JAK-STAT inhibitors in Immune mediated diseases: an overview","volume":"89","author":"Shah","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.coi.2025.102601_bib6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.coi.2025.102601_bib7","article-title":"Blockade of the JAK\/STAT pathway inhibits inflammation and bone formation in two murine models of spondyloarthritis [abstract]","volume":"70","author":"Maeda","year":"2018","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.coi.2025.102601_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm"},{"key":"10.1016\/j.coi.2025.102601_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216658","article-title":"Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells","volume":"81","author":"Raychaudhuri","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102601_sbref10","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-211046","article-title":"Regulatoryrole of the JAK STAT kinase signaling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102601_bib11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clim.2010.05.003","article-title":"Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population","volume":"136","author":"Chen","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2025.102601_bib12","first-page":"108","article-title":"Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn\u2019s disease in a New Zealand population","volume":"690","author":"Ferguson","year":"2010","journal-title":"Mutat Res"},{"key":"10.1016\/j.coi.2025.102601_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102601_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2025.102601_sbref15","article-title":"Regulatory role of JAK-1\/TYK2 signaling on the pannus formation: novel mechanisms for JAK inhibitors in psoriatic disease [abstract]","volume":"75","author":"Raychaudhuri","year":"2023","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.coi.2025.102601_sbref16","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1111\/1756-185X.13732","article-title":"Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET","volume":"22","author":"Raychaudhuri","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.coi.2025.102601_bib17","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102601_bib18","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102601_bib19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.coi.2025.102601_bib20","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","article-title":"Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis","volume":"193","author":"Works","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102601_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.685280","article-title":"From science to success? Targeting tyrosine kinase 2 in spondyloarthritis and related chronic inflammatory diseases","volume":"12","author":"Hromadov\u00e1","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.coi.2025.102601_sbref22","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2217\/imt-2021-0096","article-title":"TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases","volume":"3","author":"Gonciarz","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.coi.2025.102601_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2025.102601_bib24","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1172\/JCI126567","article-title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis","volume":"130","author":"Gracey","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102601_sbref25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102601_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102601_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2022-eular.2445","article-title":"POS1046 deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 poetyk PSO program","volume":"81","author":"Warren","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102601_bib28","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2023-2-7","article-title":"Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far","volume":"12","author":"Martins","year":"2023","journal-title":"Drugs Context"},{"key":"10.1016\/j.coi.2025.102601_bib29","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102601_bib30","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102601_bib31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102601_bib32","first-page":"1009","article-title":"Efficacy and safety of brepocitinib (tyrosine kinase 2\/janus kinase 1 inhibitor) for the treatment of active psoriatic arthritis: results from a phase 2b randomized controlled trial","volume":"73","author":"Mease","year":"2021","journal-title":"Arthr Rheu"},{"key":"10.1016\/j.coi.2025.102601_sbref33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0190-9622(08)81760-4","article-title":"Are sensory nerves essential for the pathogenesis for psoriasis?","volume":"28","author":"Raychaudhuri","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102601_bib34","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.0022-202X.2003.12602.x","article-title":"K252a, a high affinity NGF receptor blocker improves psoriasis: an in vivo study using the SCID mouse-human skin model","volume":"122","author":"Raychaudhuri","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102601_bib35","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2340\/00015555-2047","article-title":"Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis","volume":"95","author":"Roblin","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coi.2025.102601_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/0019-5154.123499","article-title":"mTOR signalling cascade in psoriatic disease: double kinase mTOR inhibitor a novel therapeutic target","volume":"59","author":"Raychaudhuri","year":"2014","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.coi.2025.102601_bib37","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/jid.2013.3","article-title":"1alpha,25-Dihydroxyvitamin-D3-3-bromoacetate regulates AKT\/mTOR signaling cascades: a therapeutic agent for psoriasis","volume":"133","author":"Datta Mitra","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102601_bib38","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/art.30278","article-title":"Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent","volume":"63","author":"Saxena","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102601_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cyto.2012.06.316","article-title":"IL-22 induced cell proliferation is regulated by PI3K\/Akt\/mTOR signaling cascade","volume":"60","author":"Mitra","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.coi.2025.102601_bib40","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1365-2133.2001.04376.x","article-title":"Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial","volume":"145","author":"Reitamo","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102601_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/dth.12176","article-title":"Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis","volume":"28","author":"Wei","year":"2015","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coi.2025.102601_bib42","article-title":"mTOR blockade by rapamycin in SpA: impact on inflammation and new bone formation in vitro and in vivo","volume":"27","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102601_bib43","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1093\/rheumatology\/kead022","article-title":"ROR\u03b3t inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating \u03b3\u03b4-T cells","volume":"62","author":"Mortier","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102601_bib44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature10075","article-title":"Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand","volume":"472","author":"Solt","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coi.2025.102601_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/2040622315617354","article-title":"Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases","volume":"7","author":"D'Ambrosio","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.coi.2025.102601_bib46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.110.176487","article-title":"The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation","volume":"337","author":"Piali","year":"2011","journal-title":"J Pharm Exp Ther"},{"key":"10.1016\/j.coi.2025.102601_bib47","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/med.21456","article-title":"A3 adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy","volume":"38","author":"Jacobson","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.coi.2025.102601_bib48","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/jdv.19811","article-title":"COMFORT-1 Study Investigators. Efficacy and safety of piclidenoson in plaque psoriasis: results from a randomized phase 3 clinical trial (COMFORT-1)","volume":"38","author":"Papp","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102601_bib49","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1517\/14728222.2014.920325","article-title":"Therapeutic potential of STAT4 in autoimmunity","volume":"18","author":"Liang","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.coi.2025.102601_bib50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11926-024-01144-x","article-title":"JAK-STAT signaling and beyond in the pathogenesis of spondyloarthritis and their clinical significance","volume":"26","author":"Raychaudhuri","year":"2024","journal-title":"Curr Rheuma Rep"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:04:40Z","timestamp":1779084280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"alternative-id":["S0952791525000779"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102601","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moving beyond the Janus kinase signaling kinases in the pathogenesis and treatment of psoriasis and psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102601"}}